Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > BUSINESS
BUSINESS
- ViiV Healthcare Wins US Regulatory Approval for Anti-HIV Drug Dolutegravir
August 15, 2013
- Generics of the Major Anticancer Drug TS-1 Launched by Just 2 Companies Due to Development Hurdles
August 15, 2013
- Eisai Paid a Total of 18.7 Billion Yen to Doctors and Medical Institutions, 1.1 Billion Yen for Research Grants
August 14, 2013
- Sitagliptin Filed for Combination Therapy with Glinides: MSD, Ono
August 14, 2013
- Novartis AG to Cease Worldwide Development of Afinitor for Hepatocellular Carcinoma
August 14, 2013
- Chugai Paid 18.1 Billion Yen to Healthcare Professionals in 2012
August 13, 2013
- Novartis’s 11-Year Research Grants to 5 Universities Total 1.1 Billion Yen
August 13, 2013
- JPWA Operating Profit Margin at 0.63%, First Gross Profit Margin Rise Since FY2007
August 13, 2013
- MSD Paid 20.8 Billion Yen to Doctors, Medical Institutions in FY2012
August 13, 2013
- Payments to Healthcare Professionals by 10 Drug Makers Top 150 Billion Yen
August 13, 2013
- Otsuka Holdings’ Pharmaceutical Sales Rise 14.8%, Global Sales for Abilify Up 21.9% in April-June Period
August 12, 2013
- Novartis Corrects Third-Party Investigation Report on Diovan Studies
August 12, 2013
- DSP to Set Up Regenerative & Cellular Medicine Office for Integrated Management of All Related Functions
August 12, 2013
- AZ’s Exenatide Promotion to Break Free from Weight-Loss Image of GLP-1 Receptor Agonists
August 9, 2013
- Ethical Drug Sales Down 0.1% in June: Crecon Report
August 9, 2013
- Seikagaku Obtains Favorable Results from PIII Study of Condoliase for Lumbar Disc Herniation, Plans to File NDA in Japan During FY2013
August 9, 2013
- Meiji Seika Pharma Changes New Drug Plan in the CNS Field; Filing and Launch of Asenapine to Take Priority
August 9, 2013
- Sawai Lifts Limit Restrictions on Atelec Generic Supplies
August 8, 2013
- DSP Aims for Better Communications with Wholesalers, Regulators with Tokyo-Osaka Two Head Office System
August 8, 2013
- Top 4 Wholesalers Report Average Price Agreement Rate of 63.4% at End of June, Down 7.5 Points from 2 Years Prior
August 8, 2013
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…